Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofil Chemicals & PharmaceuticalsBOM:524396 -0.99%68 Interest Coverage is 103.14 as of Jun. 2026, which is 656% above its 10-year median of 13.64. GuruFocus rates BOM:524396 with a GF Score™ of 68/100 and a GF Value™ of ₹48.52 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 676 Drug Manufacturers companies, Biofil Chemicals & Pharmaceuticals ranks better than 88.76% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biofil Chemicals & Pharmaceuticals's
Operating Income
for the
three
months ended in Jun. 2026 was ₹0.7 Mil. Biofil Chemicals & Pharmaceuticals's Interest Expense for the
three
months ended in Jun. 2026 was ₹-0.0 Mil.
Biofil Chemicals & Pharmaceuticals's interest coverage for the quarter that ended in Jun. 2026 was 103.14.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Biofil Chemicals & Pharmaceuticals's Interest Coverage or its related term are showing as below:
BOM:524396'
s Interest Coverage Range Over the Past 10 Years
Min: 4.11 Med: 13.64 Max: 340
Current: 340
BOM:524396's Interest Coverage is ranked better than 88.76% of 676
companies
in the Drug Manufacturers industry
Industry Median: 13
vs BOM:524396: 340.00
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biofil Chemicals & Pharmaceuticals Interest Coverage Related Terms
Biofil Chemicals & Pharmaceuticals Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (BOM:524396) has a Interest Coverage of 103.14 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. This is 656% above median its historical median of 13.64. Over the past decade, Biofil Chemicals & Pharmaceuticals' Interest Coverage has ranged from 4.11 to 340.00. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #76 out of 676 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is Biofil Chemicals & Pharmaceuticals' Interest Coverage too high?
Biofil Chemicals & Pharmaceuticals' current Interest Coverage of 103.14 is 656% above median its 10-year median of 13.64. Over the past 10 years, this metric has ranged from a low of 4.11 to a high of 340.00. The Drug Manufacturers industry median Interest Coverage is 13.00. Biofil Chemicals & Pharmaceuticals' value of 103.14 is 693.4% above this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #76 out of 676 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #76 out of 676 companies for Interest Coverage. This places Biofil Chemicals & Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.00. Biofil Chemicals & Pharmaceuticals' value of 103.14 is 693.4% above this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own Interest Coverage has ranged from 4.11 to 340.00 over the past decade. While the company's 10-year median is 13.64 vs. the industry median of 13.00, Biofil Chemicals & Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.00, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current Interest Coverage of 103.14 is 693.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current Interest Coverage is 103.14, which is 656% above median its own 10-year median of 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (BOM:524396) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹48.52, compared to a current price of ₹31.90 — trading 34.3% below its estimated fair value. The current Interest Coverage is 103.14, which is 656% above median its 10-year median of 13.64 and 693.4% above the Drug Manufacturers industry median of 13.00. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (BOM:524396), the current Interest Coverage is 103.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (BOM:524396) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹31.90 is trading 34.3% below its estimated GF Value™ of ₹48.52.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for BOM:524396:
Interest Coverage: 103.14 (656% above median its 10-year median of 13.64)
GF Value™: ₹48.52 vs. price of ₹31.90 (34.3% below fair value)
Industry Position: 693.4% above the Drug Manufacturers median (#76 of 676)
No single metric tells the full story. See the BOM:524396 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
68GF Score
Get the complete analysis for BOM:524396
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524396 has been successfully added to your 
